CIK cells are the main effective cell group of the Immuncel LC strain and have the characteristics of both T cells and NK cells. CIK differentiated from umbilical cord blood is generally low in allogeneic reactivity to HLA (human leukocyte antigen), so the risk of graft versus host reaction (GVHD) is low, so it can be used as an allogeneic cell therapy. The side explained.
In addition, it is known that cancer cells can be recognized and removed without antigen presentation by MHC (main histocompatibility complex), thereby effectively inhibiting cancer cell removal and recurrence.
GC Green Cross Cell has secured a platform technology for CAR-T treatments by utilizing the CAR structure obtained through research on CAR-T treatments so far.
In addition, it plans to develop a universally available freeze formulation of CAR-CIK treatment by combining the experience of producing CIK treatments obtained through the production of ImmuncellLC for more than 10 years.
In addition to the development of CAR-CIK cell therapy products, GC Green Cross Cell plans to accelerate the expansion of the CDMO business for consignment development and production of cell and gene therapy products. He already has the experience of carrying out a number of projects such as Celid, GC Green Cross Lab Cell, and Atiba in the US.
GC Green Cross Cell CEO Lee Gain-joo said, “CIK cells are a major component of Immuncel LC, and have already produced products for more than 10 years and have been administering treatments to more than 5,000 patients.” If successful, cancer patients will be able to be easily treated with off-the-shelf cell gene therapy at any time without restrictions on blood collection, manufacturing period, and side effects.”
[한경우 매경닷컴 기자 [email protected]]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]